SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Investors are actively debating Ethereum's role as a long-term hedge against monetary debasement and a settlement layer for tokenized assets, while community sentiment remains split over recent whale selling and price volatility. Discussions are heavily focused on the impact of shifting liquidity conditions, regulatory clarity, and the potential for a technical breakout if the asset sustains key support levels.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401jK is gaining traction as a community-driven "Resist & Retire" movement, with investors actively discussing its role as a satirical alternative to traditional retirement plans. The community is focused on long-term accumulation, IRL raids, and educational content, positioning the token as a narrative-led project that aims to challenge systemic financial corruption.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust is currently at the center of a polarized market conversation as investors weigh institutional adoption against intense macroeconomic volatility driven by geopolitical tensions in the Middle East. While community sentiment remains divided between those expecting a massive short squeeze as supply tightens and others cautioning that technical indicators suggest further downside risk, discussions are heavily focused on the interplay between crypto's role as an institutional asset and its potential vulnerability to broader financial shocks.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinal Infrastructure Group is attracting attention due to significant insider buying and positive analyst revisions, fueling a steady upward momentum. Investors are actively discussing its status as a 'slo-mo' IPO, noting the stock's resilient, gradual grind higher despite currently flying under the broader market radar.

iShares Trust - iShares Core S&P 500 ETF

iShares Core S&P 500 ETF

Investors are closely monitoring IVV and the broader S&P 500 as markets contend with lingering concerns over rising geopolitical tensions and potential economic volatility. The community remains focused on long-term resilience and dividend strategies, while debates continue over whether to buy current dips or brace for deeper corrections amidst uncertainty.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant trading momentum driven by its unique model of combining blockchain technology with live entertainment events and speculative anticipation surrounding potential high-profile corporate partnerships. While enthusiasts are actively tracking technical breakout levels and upcoming festival appearances, the community remains divided between those bullish on the project's real-world utility and skeptics warning of high volatility and potential downside risks.

Ethereum Classic

Ethereum Classic is experiencing renewed community interest and speculative movement, with traders actively debating its potential for a breakout after a prolonged period of consolidation. While some participants are wary of potential pump-and-dump volatility, many long-term holders are highlighting the coin's proof-of-work status and historical patterns as catalysts for a potential price recovery.

WorldFinancial

WorldFinancial (WLFI) is trending as investors debate the impact of high-profile political ties and an upcoming crypto forum at Mar-a-Lago amid intense scrutiny from government probes into foreign investment deals. The community remains deeply divided, with bulls betting on institutional adoption and a short squeeze, while bears highlight risks related to token dilution, regulatory investigations, and skepticism over the project's long-term utility.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the semiconductor sector rides a massive wave of AI infrastructure demand, with investors focused on the critical role of advanced packaging as a supply chain bottleneck. Community discussion is dominated by the company's strategic expansion of its Arizona campus, its status as a key domestic partner for major chipmakers, and its position as an overlooked "pick and shovel" play in the current semiconductor super cycle.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductor stocks are currently at the center of market volatility as investors weigh the tension between persistent AI infrastructure demand and rising concerns over unsustainable capital expenditure and geopolitical risk. The community is actively debating whether the sector remains a structural market leader or is forming a topping pattern, with significant institutional activity in short-dated options suggesting a rise in hedging against a potential pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Jefferies had predicted that IOVA could see a 5%-15% move on Replime’s drug getting rejected.&nbsp;</li><li>According to Chardan analyst Geulah Livshits, RP1’s rejection is a positive for Iovance's Amtagvi's near-term competitive position.</li><li>Iovance story "remains centered on" Amtagvi's sales acceleration and margin expansion in 2026, according to Jefferies.</li></ul>Shares of Iovance Biotherapeutics Inc. (IOVA) garnered retail attention on Friday in light of an aspiring rival’s drug failing to get the nod from the U.S. Food and Drug Administration.IOVA shares closed down 8% on Friday, surprising retail investors and analysts alike. Jefferies had predicted that IOVA could see a 5%-15% move on Replimune’s drug getting rejected.Earlier on Friday, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">refused</a> to approve Replimune’s (REPL) investigational melanoma drug RP1. The agency said in a letter to the company that the data submitted by Replimune as part of its application seeking approval of the drug is “insufficient to conclude substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.Iovance’s Amtagvi cellular therapy is already approved as a treatment for people with previously treated melanoma that has spread or cannot be removed by surgery. The drug was granted accelerated approval in February 2024. The company recorded Amtagvi revenue of about $220 million for the full year 2025 in the U.S.<h2 class="st-heading-2">How Did Retail Traders React?</h2>A Stocktwits user expressed surprise at the stock closing down on the good news.<stembedurl>https://www.stocktwits.com/KingCuerv0/message/649991039</stembedurl>Yet another echoed the sentiment.<stembedurl>https://www.stocktwits.com/lebranjames/message/649990274</stembedurl>Another user opined that the stock may be down over concerns about FDA raising the bar for trials.<stembedurl>https://www.stocktwits.com/mlftt/message/649991395</stembedurl>Yet another user sounded optimism for clarity on sentiment around the stock on Monday. &nbsp;“Good news after good news lately, don’t let the price action tell you otherwise,” they said.<stembedurl>https://www.stocktwits.com/Morrito23/message/649985521</stembedurl>Overall retail sentiment around IOVA jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. Retail chatter around IOVA rose 75%, according to platform data.<h2 class="st-heading-2">Analyst Take</h2>According to data from Koyfin, eight of the 11 analysts covering IOVA rate it ‘Buy’ or higher, while three rate it ‘Hold’. There are no ‘Sell’ ratings of the stock.The average 12-month price target on the stock is $9, representing a potential upside of about 144%.According to Jefferies analyst Andrew Tsai, the rejection for RP1 means one less competitor for Iovance in the near term though Replimune was “technically not an overhang.” Iovance story "remains centered on" Amtagvi's sales acceleration and margin expansion in 2026, he said. The analyst has a ‘Buy’ rating and $12 price target on the shares.Chardan analyst Geulah Livshits also kept &nbsp;a ‘Buy’ rating on Iovance Biotherapeutics (IOVA) with a $16 price target after Replimune (REPL) update. RP1’s rejection is a positive for Iovance's Amtagvi's near-term competitive position, the analyst told investors in a research note. However, the firm added that more direct competition from cell therapies "could be on the horizon" in 2027.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has gained 21% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cue-stock-on-track-for-best-day-in-history-why-is-retail-optimistic/cZJ0N5KRItC">CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why

Earlier on Friday, the FDA refused to approve Replimune’s investigational melanoma drug RP1, which was a likely contender for Iovance’s Amtagvi. 

Equity

Earlier on Friday, the FDA refused to approve Replimune’s investigational melanoma drug RP1, which was a likely contender for Iovance’s Amtagvi. 


Iovance Biotherapeutics' (IOVA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued a "buy" rating and set a $16.00 target price on shares of Iovance Biotherapeutics in a report on Friday...

Promising Biotech Stocks To Follow Today - April 10th

Danaher, Vertex Pharmaceuticals, Iovance Biotherapeutics, argenex, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business is developing, manufacturing, or commercializing bi...

Iovance Biotherapeutics (NASDAQ:IOVA)  Shares Down 6.6%   - Here's Why

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.6% - Should You Sell...

Investors Purchase High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders acquired 23,006 call options on the company. This is an...

Zacks Research Brokers Boost Earnings Estimates for IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at Zacks Research boosted their Q1 2026 EPS estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, April 8th. Zacks Research analyst Team now expects that the biotechnology company will earn...

<ul class="summary-bullets"><li>Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels.</li><li>Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product revenue in 2025.</li><li>RP1, in combination with Nivolumab, shrank tumors in about one-third of PD-1-failed melanoma patients.</li></ul>Shares of Replimune Group, Inc. (REPL) and Iovance Biotherapeutics, Inc. (IOVA) are back in focus on Friday ahead of an FDA decision on the former's lead immunotherapy candidate RP1, as investors compare a near-term approval catalyst with an already approved melanoma therapy.<a href="https://stocktwits.com/symbol/REPL">REPL stock</a> is on track for its worst weekly decline in nearly seven months after logging its biggest single-session drop in over six months on Wednesday. Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/IOVA">IOVA shares</a> are poised to snap a four-week losing streak after jumping 16% on Thursday, marking their best session in over a month.Koyfin estimates give Iovance the early lead on upside, but today’s RP1 verdict could determine whether Replimune closes the gap in a single catalyst move.<h2 class="st-heading-2">RP1 Decision Looms For Replimune</h2>Replimune’s lead candidate RP1, in combination with Nivolumab, an immunotherapy that helps the immune system attack cancer cells, is under U.S. Food and Drug Administration (FDA) review for patients with advanced melanoma whose disease has progressed after prior PD-1 therapy, with the Prescription Drug User Fee Act (PDUFA) decision due Friday.The company’s commercial readiness activities are already underway to support the launch if approval is granted. Trial results from last year showed that RP1 combined with Nivolumab shrank tumors in about one-third of patients whose melanoma had already stopped responding to standard PD-1 immunotherapy, including complete tumor disappearance in 15% of patients.Consensus estimates tracked by Koyfin place Replimune’s average price target at $12.86, implying a 116% upside from current levels. The stock is covered by seven analysts, with one rating it ‘Strong Buy’, four ‘Buy’, and two ‘Hold’, resulting in an overall consensus rating of ‘Strong Buy’.Several analysts turned bullish after the FDA accepted the BLA resubmission in October. H.C. Wainwright raised its probability of approval to 85% from 50%, while Piper Sandler expects a potential mid-2026 launch. JPMorgan added that the “totality of the RP1 data in the refractory melanoma setting is compelling and warrants approval.”<h2 class="st-heading-2">Amtagvi Gives Iovance Commercial Edge</h2>Unlike Replimune, Iovance already has an approved therapy on the market. The FDA approved Amtagvi in 2024 as the first therapy made from a patient’s own tumor-fighting immune cells for people with advanced melanoma that cannot be removed with surgery or has spread after earlier PD-1 immunotherapy stopped working.The company reported $264 million in total product revenue in 2025, including $220 million from Amtagvi, marking its first full calendar year of launch. The company flagged increasing treatment-center adoption and manufacturing improvements expected to continue this year.Consensus estimates place Iovance’s average analyst price target at $9, representing a 124% upside from the stock’s last close. The stock is covered by 11 analysts, with two rating it ‘Strong Buy’, six ‘Buy’, and three ‘Hold’, supporting a consensus rating of ‘Strong Buy’.Iovance is also expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform into several cancers beyond melanoma. Updated data in February showed that 44% of melanoma patients responded to Amtagvi, while additional trials are underway in non-small-cell lung cancer, sarcoma and frontline melanoma combinations. The FDA has also granted Fast Track designation to Amtagvi in advanced non-small-cell lung cancer.<h2 class="st-heading-2">How Do Retail Traders Feel About REPL, IOVA?</h2>On Stocktwits, retail sentiment for REPL was ‘bearish’ amid ‘extremely high’ message volume, while sentiment toward IOVA was ‘bullish’ amid ‘high’ message volume.One user&nbsp;<a href="https://stocktwits.com/Bob_Whitley/message/649897269">warned</a> that approval appeared unlikely ahead of the decision, saying "Take off the blinders, the stock [REPL] tanked this week on no news, IOVA had a surge, the trial design was basically picked apart at the joints in the last CRL."<stembedurl>https://stocktwits.com/Bob_Whitley/message/649897269</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/RunnersOnly4/message/649889153">said</a>, “Why gamble with REPL when you have a sure thing with IOVA at a lower price?”<stembedurl>https://stocktwits.com/RunnersOnly4/message/649889153</stembedurl>Over the past year, shares of REPL have fallen 19%, while IOVA stock has risen 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-dips-hk-after-es9-debut-what-went-wrong/cZJ0cCeRIsD">Nio Stock Dips In HK After ES9 Debut: What Went Wrong?</a>

Over the past year, shares of REPL have fallen 19%, while IOVA stock has risen 23%. (Photo credit: Getty Images)

REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays

REPL stock is heading for its worst weekly loss in nearly seven months ahead of the FDA decision on RP1.

<ul class="summary-bullets"><li>FDA is slated to decide on potential rival Replimune’s application for RP1 in the treatment of advanced melanoma by April 10.</li><li>Iovance’s Amtagvi cellular therapy is already approved as a treatment for people with previously treated melanoma that has spread or cannot be removed by surgery.</li><li>The company recorded Amtagvi revenue of about $220 million for the full year 2025 in the U.S.</li></ul> Shares of Iovance Biotherapeutics (IOVA) closed up 16% on Thursday as investors await the U.S. Food and Drug Administration’s decision on its aspiring competitor Replimune’s (REPL) skin cancer drug.IOVA stock has closed in the green for three consecutive days and recorded its best single-day gain on Thursday since late February.The FDA is slated to decide on Replimune’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.Iovance’s Amtagvi cellular therapy is already approved as a treatment for people with previously treated melanoma that has spread or cannot be removed by surgery. The drug was granted accelerated approval in February 2024. &nbsp;The company recorded Amtagvi revenue of about $220 million for the full year 2025 in the U.S.<h2 class="st-heading-2">Retail Chimes In</h2>A Stocktwits user said that rejection for Replimune’s drug will be the “end of the last anchor” holding IOVA down.<stembedurl>https://www.stocktwits.com/EvrytIsNothingWithaTwist/message/649873087</stembedurl>Another expressed anticipation for the decision.<stembedurl>https://www.stocktwits.com/medinapj/message/649874467</stembedurl><h2 class="st-heading-2">RP1’s Past Issues</h2>In late July 2025, the FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data, and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around IOVA stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.Meanwhile, sentiment around REPL trended in ‘extremely bearish’ territory at the time of writing. &nbsp;<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has gained 23% over the past 12 months while <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> fell 19%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-gemi-stock-up-eleven-percent/cZJWX2VRIsh">GEMI Stock On Track To Record Best Session In Over A Month On Acquisition Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IOVA Stock Clocks Best Session Since February As Retail Awaits FDA Decision On Rival Drug

IOVA stock closed in the green for the past three days and recorded its best single-day gain on Thursday since late February.

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 7.1% - Time to Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.1% Higher - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving Average - Here's What Happened

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Crosses Below 50 Day Moving Average - Here's What Happened...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

The denial of a key competitor's BLA clears the field, leaving the firm as the dominant player in the advanced melanoma market.

Recruiting high-caliber ex-FDA leaders provides a strategic advantage for navigating the stringent regulatory landscape for cell therapies.

Massive short interest coupled with positive sentiment from competitor failures is sparking intense debate over potential near-term price surges.

Accelerating expansion and deeper utilization within the Authorized Treatment Center network serves as a key catalyst for projected 2026 growth.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.15	--	--	N/A
Q4 '25	-$0.17	-$0.18	-2.90%	MISSED
Q3 '25	-$0.26	-$0.25	2.98%	BEAT
Q2 '25	-$0.28	-$0.33	-16.70%	MISSED
Q1 '25	-$0.24	-$0.36	-48.93%	MISSED

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest IOVA News

IOVAIovance Biotherapeutics Inc